SCHEMBL30983502

SCHEMBL30983502

CN(C)C(=O)COc1ccc(-c2nc3c(OC4(C)CC4)ncnc3n2Cc2ccccc2)c(Cl)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ PIK3CD O00329 3/20 0.36
▸ PDK2 Q15119 1/20 0.35
▸ ACSS2 Q9NR19 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ AKT2 P31751 1/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAT2A P31153 1/20 0.34
▸ F2 P00734 1/20 0.34
▸ F10 P00742 1/20 0.34
▸ PRSS1 P07477 1/20 0.34
▸ MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30983954 0.92 PLA2G2A (0.39) PIK3CDKDM4EKMT2ACNR1CNR2
SCHEMBL30984034 0.91 PIK3CD (0.37) PIK3CDKDM4EALDH1A1GAAHPGD
SCHEMBL30983924 0.91 PLA2G2A (0.38) PIK3CDAKT1AKT2KMT2ACNR1
SCHEMBL30983512 0.89 KMT2A (0.36) PIK3CDPDK2ACSS2SMN1; SMN2MEN1
SCHEMBL31269100 0.89 PIK3CD (0.34) PIK3CDPDK2KDM4EALDH1A1HPGD
SCHEMBL31321937 0.88 PLA2G2A (0.40) PIK3CDPDK2
SCHEMBL30983480 0.87 F2 (0.39) PIK3CDALDH1A1HSD17B10F2F10
SCHEMBL30983449 0.87 ALDH1A1 (0.42) RAB9APIK3CDPDK2SMN1; SMN2KDM4E
SCHEMBL30983424 0.87 HTR1D (0.43) NPC1RAB9ASMN1; SMN2KDM4EALDH1A1
SCHEMBL30983817 0.86 CNR1 (0.41) PIK3CDSMN1; SMN2ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP claimed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB NPC1 3576/4885RAB9A 2104/4885PIK3CD 434/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB NPC1 3576/4885RAB9A 2104/4885PIK3CD 434/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB NPC1 3576/4885RAB9A 2104/4885PIK3CD 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback